The coronavirus pandemic has shown no signs of abating even after the passing of many months and the demand for viable treatments have gone through the roof. Hence, Relief Therapeutics Holdings AG (OTCPK:RLFTF) stock has come into sharp focus in the past month among bargain hunting investors, and it has rallied strongly in August due to a slew of positive news.
RLFTF has rallied by as much as 1650% in the month of August so far and this past Friday, the Relief stock continued its upward move as it gained another 28%. In light of such developments, it could be worthwhile for investors to take a closer look at the company.
Last week, the company announced that it managed to discover a potentially effective COVID 19 killer. The company is currently engaged in an advanced clinical trial of its coronavirus treatment RLF 100. The product is meant for stopping the effects of COVID 19 and on August 11 the company released highly positive the results from patients who had been allowed Compassionate Use of the product.
It was revealed that patients who had been dependent on a ventilator were actually able to return home in a matter of five days. That is a stunning performance and there is rightly a lot of optimism around the Relief Therapeutics stock.
On the other hand, it should also be noted that RLF 100 is easy to scale up and manufacture without incurring great expense. Hence, if the product does get approval, then Relief is going to be able to mass-produce the medicine and possibly capture a significant portion of the huge market worldwide. If the clinical trial manages to mirror the performance of the Compassionate Use results, then RLF 100 could be awarded approval quickly and that could send the shares even higher. It goes without saying that investors could consider keeping the stock in their watch lists at this point and keep track of the myriad developments.
It is likely that the stock is going to be the focus among many investors this week as well and it remains to be seen if it can continue to add to its gains. The company made a similar announcement earlier in August. Along with its partner NeuroRx, Relief announced that RLF 100 managed to bring market improvement in the condition of patients suffering from extreme respiratory problems brought about by COVID 19. That was the first trigger behind the rally in the stock this month. Sign up below for breakout alerts on RLFTF and other breakout stocks.